<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136535</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-L031</org_study_id>
    <nct_id>NCT04136535</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC</brief_title>
  <acronym>PCA</acronym>
  <official_title>A Multicenter, Randomized, Phase II Study of Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Advanced or Locally-advanced Osimertinib-resistant Non-squamous Non-small Cell Lung Cancer (ALTER-L031)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed
      and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced
      Osimertinib-resistant non-squamous non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin use 4 cycles,then
      continue pem and anlotinib until PD

      Pemetrexed and Carboplatin use 4 cycles,then continue pem until PD

      TO see the different of PFS and OS and safety between the two group
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months</time_frame>
    <description>Progress free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed and Carboplatin with Anlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed and Carboplatin without Anlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed，500mg/m²，ivgtt ，d1，q3w</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin，AUC 5.0，ivgtt，d1，q3w，</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib ，12 mg，po，qd，d1-14，q3w；</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. 18 Years to 75 Years patients voluntarily participate in this study, signed and dated
        informed consent with good compliance and follow-up; 2. Confirmed as locally advanced and /
        or metastatic non-squamous non-small cell lung cancer (NSCLC) by cytology or histology, the
        diagnosis should be completed at least 6 months after the end of chemotherapy if adjuvant
        chemotherapy and / or neoadjuvant chemotherapy received (diagnosis based on sputum smear is
        not accepted) ; 3. Presence of EGFR activating mutations and previously disease progression
        to Osimertinib (previously treated with 1st / 2nd generation EGFR-TKI or not)； 4. At least
        one target lesion that has accurate measurement by magnetic resonance imaging (MRI) or
        computed tomography (CT) (conventional CT≥20 mm or spiral CT≥10 mm) in at least 1
        direction; 5. Life expectancy is at least 3 months; 6. ECOG PS Scoring: 0~1 point; 8. The
        main organs function are normally, the following criteria are met:

        Blood routine examination criteria (no blood transfusion and blood products within 14 days,
        no correction by G-CSF and other hematopoietic stimuli):

        i) hemoglobin (HB) ≥90g/L ii) neutrophil absolute (ANC) ≥1.5×109/L iii) platelet (PLT)
        ≥80×109/L Biochemical tests meet the following criteria i) total bilirubin (TBIL) ≤1.5
        times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate
        aminotransferase (AST)≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii)
        serum creatinine (Cr) ≤1.25 ULN or creatinine clearance (CCr)≥45mL/min (Cockcroft-Gault
        formula).

        9.Female patients of childbearing age agree that contraceptive measures must be used within
        the study period and within 8 weeks after the end of the study drug treatment. The serum or
        urine test indicates unpregnancy within 7 days prior to the study. Male patients agree to
        have contraceptive use during the study period and within 8 weeks after the end of the
        study period or have had surgical sterilization.

        Exclusion Criteria:

          1. Patients with small cell lung cancer (including small cell carcinoma and non-small
             cell carcinoma mixed lung cancer) and lung adenosquamous carcinoma mixed with squamous
             carcinoma;

          2. Active brain metastases, cancerous meningitis, spinal cord compression, or imaging CT
             or MRI screening for brain or pia mater disease (a patient with brain metastases who
             have completed treatment and stable symptoms in 21 days before enrollment may be
             enrolled, but should be confirmed by brain MRI, CT or venography evaluation as no
             cerebral hemorrhage symptoms);

          3. Imaging (CT or MRI) shows that the distance between tumor lesion and the large blood
             vessel is ≤ 5 mm, or there is a central tumor that invades the local large blood
             vessel and the distance between tumor and bronchial tree is ≤ 2 cm; or there is a
             significant pulmonary cavity or necrotizing tumor;

          4. Uncontrollable hypertension (systolic blood pressure ≥140 mmHg or diastolic blood
             pressure ≥90 mmHg after optimal medical treatment);

          5. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial
             infarction above grade II, poorly controlled arrhythmias (including men with QTc
             interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV
             Insufficient function, or cardiac color Doppler ultrasound examination indicates left
             ventricular ejection fraction (LVEF) &lt;50%;

          6. Abnormal blood coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or
             APTT &gt; 1.5 ULN), with bleeding tendency or undergoing thrombolytic or anticoagulant
             therapy;

          7. Urine routine test protein ≥++, and confirmed 24 hours urine protein&gt; 1.0 g;

          8. There is currently a peripheral neuropathy of ≥CTCAE 2 degrees, except for trauma;

          9. Respiratory syndrome (≥CTC AE grade 2 dyspnea), serous effusion (including pleural
             effusion, ascites, pericardial effusion) requiring surgical treatment;

         10. Long-term unhealed wounds or fractures;

         11. Serious infection (≥CTC AE Level 2 infection) requiring systemic antibiotics;

         12. decompensated diabetes or other ailments treated with high doses of glucocorticoids;

         13. Active or chronic hepatitis C or/and hepatitis B infection;

         14. Factors that have a significant impact on oral drug absorption, such as inability to
             swallow, chronic diarrhea, and intestinal obstruction;

         15. Patients have undergone major surgery within 4 weeks before enrollment or have severe
             trauma, fracture and ulcer;

         16. Severe weight loss (greater than 10%) within 6 weeks prior to enrollment;

         17. Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3 months
             prior to enrollment; or significant clinically significant bleeding symptoms or
             defined bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric
             ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis;

         18. Events of venous/ arterious thrombosis occurring within the first 12 months prior to
             enrollment, such as cerebrovascular accidents (including transient ischemic attacks,
             cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary
             embolism;

         19. Patients have contraindication to platinum drugs (Cisplatin/Carboplatin) and cytotoxic
             drug (Pemetrexed);

         20. Patients have anaphylactic reaction due to Anlotinib Hydrochloride or the excipient in
             investigational drug.

         21. Planned for systemic anti-tumor therapy during the study period or within 4 weeks
             prior to enrollment, including cytotoxic therapy, signal transduction inhibitors,
             immunotherapy (or use mitomycin C within 6 weeks prior to receiving investigational
             drug). Radiation-rehabilitation radiotherapy (EF-RT) was performed within 4 weeks
             before enrollment or limited-field radiotherapy was performed for planned tumor
             lesions within 2 weeks before enrollment.

         22. Patients with other situations which are not suitable for the study according to the
             researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chang j hua, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chang J hua, PD</last_name>
    <phone>18017312689</phone>
    <email>changjianhua@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiang h wu, dorctor</last_name>
    <phone>13482888167</phone>
    <email>xhwu2011@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chang j hua, PD</last_name>
      <phone>18017312689</phone>
      <email>changjianhua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.</citation>
    <PMID>27959700</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>primary care physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

